FDA approves durvalumab for muscle-invasive bladder cancer: a new standard in neoadjuvant and adjuvant therapy.
作者信息
Hassan Ibrahim Nagmeldin, Ibrahim Muhsin Nagmeldin Hassan, Abuassa Nagmeldin
机构信息
Faculty of Medicine, University of Khartoum, Khartoum, Sudan.
Faculty of Medicine, Sudan University of Science and Technology, Khartoum, Sudan.
出版信息
Ann Med Surg (Lond). 2025 May 20;87(7):4011-4013. doi: 10.1097/MS9.0000000000003399. eCollection 2025 Jul.
Abstract
摘要
相似文献
1
FDA approves durvalumab for muscle-invasive bladder cancer: a new standard in neoadjuvant and adjuvant therapy.
Ann Med Surg (Lond). 2025 May 20;87(7):4011-4013. doi: 10.1097/MS9.0000000000003399. eCollection 2025 Jul.
2
Cost-effectiveness of perioperative durvalumab plus neoadjuvant chemotherapy for muscle invasive bladder cancer in the United States.
Ther Adv Med Oncol. 2025 Jul 29;17:17588359251357519. doi: 10.1177/17588359251357519. eCollection 2025.
3
Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer.
N Engl J Med. 2024 Nov 14;391(19):1773-1786. doi: 10.1056/NEJMoa2408154. Epub 2024 Sep 15.
4
FDA approves durvalumab for perioperative immunotherapy for patients with muscle-invasive bladder cancer: In a prespecified analysis, the trial demonstrated a statistically significant improvement in event-free survival and overall survival.
Cancer. 2025 Jul 1;131(13):e35912. doi: 10.1002/cncr.35912.
5
Top advances of the year: Bladder cancer.
Cancer. 2025 Aug 15;131(16):e70020. doi: 10.1002/cncr.70020.
6
Neoadjuvant Immunotherapy in Bladder Cancer: Ushering in a New Era of Treatment-A Systematic Review of Current Evidence.
Eur Urol Open Sci. 2025 Aug 6;79:45-59. doi: 10.1016/j.euros.2025.07.010. eCollection 2025 Sep.
7
Cost-effectiveness analysis of perioperative durvalumab plus platin-based chemotherapy in muscle invasive bladder cancer in Germany.
Eur J Cancer. 2025 Sep 9;227:115621. doi: 10.1016/j.ejca.2025.115621. Epub 2025 Jul 10.
8
Neoadjuvant Radiotherapy Combined with Transurethral Photoselective Vaporization of Bladder Tumors and Postoperative Adjuvant Radiotherapy and Chemotherapy for T3 Muscle-Invasive Bladder Cancer: A Retrospective Case Series Study.
Photobiomodul Photomed Laser Surg. 2025 Jul;43(7):302-309. doi: 10.1089/photob.2024.0150. Epub 2025 Jun 16.
9
Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: A Systematic Review and Two-Step Meta-Analysis.
Oncologist. 2016 Jun;21(6):708-15. doi: 10.1634/theoncologist.2015-0440. Epub 2016 Apr 6.
10
Surgical Outcomes With Neoadjuvant Durvalumab Plus Chemotherapy Followed by Adjuvant Durvalumab in Resectable NSCLC.
J Thorac Oncol. 2025 Jun 20. doi: 10.1016/j.jtho.2025.06.015.
本文引用的文献
1
Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer.
N Engl J Med. 2024 Nov 14;391(19):1773-1786. doi: 10.1056/NEJMoa2408154. Epub 2024 Sep 15.
2
Epidemiology of Bladder Cancer in 2023: A Systematic Review of Risk Factors.
Eur Urol. 2023 Aug;84(2):176-190. doi: 10.1016/j.eururo.2023.03.029. Epub 2023 May 16.
3
Characterizing immune-mediated adverse events with durvalumab in patients with unresectable stage III NSCLC: A post-hoc analysis of the PACIFIC trial.
Lung Cancer. 2022 Apr;166:84-93. doi: 10.1016/j.lungcan.2022.02.003. Epub 2022 Feb 9.
4
Research Status and Outlook of PD-1/PD-L1 Inhibitors for Cancer Therapy.
Drug Des Devel Ther. 2020 Sep 8;14:3625-3649. doi: 10.2147/DDDT.S267433. eCollection 2020.
5
Treatment Options and Outcomes in Nonmetastatic Muscle Invasive Bladder Cancer.
Trends Cancer. 2019 Jul;5(7):426-439. doi: 10.1016/j.trecan.2019.05.011. Epub 2019 Jun 22.
6
Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance.
Nat Rev Clin Oncol. 2019 Sep;16(9):563-580. doi: 10.1038/s41571-019-0218-0.
Zotero 插件